With an emerging clinical trial ancillary supply chain, and little research into effective management models, it has never been more urgent for management systems to step up to an increasingly complex trial landscape. Today’s pharmaceutical landscape relies increasingly on outsourcing efforts. Meanwhile, global rules, laws, and regulations continue to evolve at a rapid pace, and pressure to expedite market approvals for new drugs mounts. Due to the intertwined factors, a new, extremely complex global ‘ancillary’ supply chain has emerged. In this era of change, how does the ancillary supply chain respond to the needs of a rapidly changing industry and create better outcomes for drug discovery organisations and their patients?
As published in International Clinical Trials Journal